ALLOSUPPRESSOR- AND ALLOHELPER-T CELLS IN ACUTE AND CHRONIC GRAFT-VS.-HOST (GVH) DISEASE

III. Different Lyt Subsets of Donor T Cells Induce Different Pathological Syndromes*

BY ANTON G. ROLINK* AND ERNST GLEICHMANN

From the Department of Immunohistopathology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology of the University of Amsterdam, The Netherlands

The graft-versus-host reaction (GVHR) is initiated by immune responses of donor T cells towards allogeneic histocompatibility antigens of the recipient. One of the possible outcomes of a systemic GVHR is acute graft-versus-host disease (GVHD), which is termed lethal GVHD (LGVHD) when fatal. Acute GVHD is characterized by a brief initial lymphoid stimulation during the first week of the GVHR (1–3), which rapidly thereafter turns into severe hypoplasia of the entire lympho-hemopoietic tissue (1–5). The clinical symptoms of acute GVHD include weight loss, aplastic anemia (1–4), hypogammaglobulinemia (1, 4), and sepsis (4). A different form of the GVHR is referred to as chronic GVHD. It is characterized by long-term stimulatory symptoms of the lymphoid tissue (1–4, 6), the formation of autoantibodies characteristic of systemic lupus erythematosus (SLE), and the development of various pathological lesions including immune-complex glomerulonephritis (ICGN) (3, 6–9). Both forms of GVHR are known to be induced by donor T cells (4, 6, 9–11), but little is known about the T cell subpopulations involved.

The dissection of the cellular mechanisms that are responsible for the hyperplastic and hypoplastic pathological GVH symptoms requires GVH-model systems that consistently induce either stimulatory or suppressive pathological symptoms. Several different GVH systems approaching this goal have been elaborated in our laboratory. In each system, parental strain T cells were injected into nonirradiated adult F1 hybrid mice differing at H-2. The results of these studies indicated that those inocula of donor cells that preferentially reacted by the alloreactive T helper (TH) cells caused the stimulatory symptoms of chronic

* This work was supported by a grant given to E. Gleichmann from the Dutch Kidney Foundation, Amsterdam, The Netherlands.

Present address: Basel Institute for Immunology, 487, Grenzacherstrasse, CH-4058 Basel, Switzerland.

Abbreviations used in this paper: B10, C57BL/10ScSn; BDF1, (B10 × DBA/2)F1; C, rabbit serum complement; dsDNA, double-stranded DNA; GVHD, graft-vs.-host disease; GVH F1, F1 mice undergoing GVH reaction; GVHR, GVH reaction; ICGN, immune-complex glomerulonephritis; LGVHD, lethal GVHD; N F1, noninjected F1; NMS, normal mouse serum; PFC, plaque-forming cell(s); SLE, systemic lupus erythematosus; SRBC, sheep erythrocyte(s); TH, T-helper; Tc, T-killer, Ts, T-suppressor.
GVHD, whereas donor cell inocula that appeared to preferentially react by their alloreactive T suppressor (T8) cells caused the suppressive pathological symptoms of acute GVHD (2–4, 7, 8, 10). Moreover, when unselected donor T cells were injected into F1 recipients, which differed solely at class II H-2 antigens (I-A/I-E), exclusively stimulatory GVHD was found; in contrast, a difference in the F1 recipients at both class I (H-2 K/D) and class II antigens was needed for the induction of acute GVHD (3, 8). Neither clear-cut stimulatory nor suppressive GVH symptoms were found in those F1 recipients that differed from the donor solely at class I H-2 antigens (3).

From studies on the allogenetic effect in vitro it is known that class II (I-A/I-E) antigenic differences activate Lyt-1*2- T H cells, which then provide maximal allohelp (12, 13). By contrast, the activation of alloreactive T8 cells requires the presence of Lyt-1*2+ cells as well as incompatibility, on the allogeneic B cells, at class I H-2 antigens (12, 13). Moreover, it seems from these studies in vitro that in order to become fully activated, the class I-reactive Lyt-1*2+ T8 cells must be induced by class II-reactive Lyt-1*2- cells (13, 14). These findings suggest that the class II (I-A/I-E) incompatibilities in the F1 recipients previously studied (3, 8) selectively activated the alloreactive T H cells out of the pool of unselected donor T cells; the activated T H cells might then have caused the formation of SLE-like autoantibodies and the development of other stimulatory GVH symptoms. In contrast, an incompatibility in the F1 recipient at both class II (I-A/I-E) and class I (K/D) antigens might have activated both the class II-reactive T H or inducer cells and the class I-reactive T8 effector cells (3). It should be noted here that alloreactive donor T8 cells, and not cytotoxic T cells, appear to be important effector cells in acute GVHD. These T8 cells seem to be the effector cells, because they suppress the physiologic proliferation of lympho-hemopoietic cells and thus cause the pancytopenia of acute GVHD (4).

The intra-H-2 requirements for the induction of either stimulatory (chronic) GVHD or suppressive (acute) GVHD (3, 8) parallel those for the induction of positive and negative allogeneic effects in vitro (12, 13). The missing link between the studies performed in vitro and the GVH experiments in vivo concerns the Lyt subsets of donor T cells that are required for the induction of either stimulatory or suppressive GVHD. We therefore injected different Lyt subsets of B10 donor T cells into (B10 X DBA/2)F1 (BDF1) mice. The results indicate that Lyt-1*2- T cells are able to induce SLE-like GVHD, but are incapable of inducing acute GVHD and LGVHD. The induction of acute GVHD and LGVHD on the other hand required unseparated donor T cells, which comprise both Lyt-1*2- and Lyt-1*2+ cells.

Materials and Methods

MICE. B10 mice (H-2b/b, Lyt-1.2, Lyt-2.2, Thy-1.2) and BDF1 hybrids (H-2b/a) were purchased from Olac 1976 Ltd. (Bicester, Oxon, U.K.). Female mice, 8–10-wk old, were used.

Preparation of Donor Cells. For induction of GVHR, single-cell suspensions of donor spleen and lymph node cells were prepared, as described (7).

Monoclonal Antibodies. Monoclonal murine anti-Lyt-1.2 (IgG2b, no. NEI-017) and anti-Lyt-2.2 (IgM, No. NEI-006) antibodies were obtained from New England Nuclear (Boston, MA). Monoclonal murine anti-Thy-1.2 (IgM, clone F7D5) was purchased from Olac 1976.
Lyt SUBSETS OF DONOR T CELLS IN GVH REACTIONS

Ltd. (Bicester, Oxon, U.K.).

Pretreatment of Donor Cells with Monoclonal Antibodies and Complement (C). Donor cells consisted either of spleen cells or of a mixture of spleen cells (2 parts) and lymph node cells (1 part). For treatment with antiserum, cell suspensions were prepared in Hepes-buffered RPMI 1640 that contained 5% fetal calf serum. Suspensions of $3 \times 10^7$ live cells/ml were incubated for 45 min on ice with either anti-Thy-1.2 serum, diluted 1 in 1,000, or anti-Lyt-1.2 or anti-Lyt-2.2 serum, each diluted 1 in 3,000. As a control, cells were treated with normal mouse serum (NMS) diluted 1 in 3,000. After incubation, the cells were spun down and resuspended with 6 ml rabbit C, which had been selected for low cytotoxicity and was diluted 1 in 12 in Hepes-buffered RPMI 1640 (not containing fetal calf serum). The suspensions were incubated for 45 min at 37°C, and thereafter the cells were washed three times. In some experiments the donor cells were treated twice with antisera and C, according to this procedure. Hereafter, cells treated with anti-Lyt-1.2 and C, anti-Lyt-2.2 and C, anti-Thy-1.2 and C, or NMS and C will be referred to as anti-Lyt-1-, anti-Lyt-2-, anti-Thy-1-, and NMS-treated cells, respectively. Unless mentioned otherwise, these cells had been treated once.

Nylon-wool Passage of Pretreated Donor Cells. In one experimental approach, B10 spleen cells, which had been pretreated twice with either NMS or anti-Lyt antibodies, were passed through nylon-wool columns (13) in order to reduce the fraction of non-T cells.

Induction of GVHR. All donor cells were injected intravenously. In the first experiment (Fig. 1 and Table I) nonirradiated mice were used as recipients. In the second experiment (Fig. 3 and Table II) the prospective BDF1 recipients were first irradiated with 750 rad by using 662-KeV gamma rays, emitted from a $^{137}$Cs source (gammarator, model 381, Isomedic) at a dose of 375 rad/min. Within the next 3 h, these mice were repopulated with $3 \times 10^7$ live untreated spleen cells obtained from syngeneic (BDF1) donors; 1 d later, the GVHR was induced by injection of B10 T cells. The donor cell inocula are specific in the results section.

Primary Anti-Sheep Erythrocyte (SRBC) Response. The primary plaque-forming cell (PFC) response to SRBC in vitro was performed as described elsewhere (13).

Clinical Signs of GVHR. Twice a week, the F1 mice undergoing GVHR (GVH F1) were inspected for symptoms of acute GVHD, such as weakness, diarrhea, and ruffled fur; weight loss was determined by weighing the mice weekly. The number of dead mice was recorded. Anemia was determined by two-weekly measurements of hematocrit. At weekly intervals, the GVH F1 mice were tested for elevated proteinuria ($\geq 300$ mg protein per 100 ml urine) by means of Albustix test sticks (no. 2872, Ames, Div. of Miles). Elevated proteinuria in GVH F1 mice is a reliable indicator of ICGN (9).

Detection of Autoantibodies. The presence of autoantibodies in the serum was determined at two-weekly intervals, starting at week 2 and lasting until week 16 after the initiation of the GVHR. Autoantibodies to erythrocytes were detected by the direct Coombs' test using anti-mouse IgG serum, as described (7). Autoantibodies to thymocytes were detected by a C-dependent cytotoxicity test, as described (7); using $^{51}$Cr-labeled thymocytes of normal BDF1 mice as target cells. Mice were scored positive for autoantibodies against thymocytes when a 1 in 5 dilution of their serum lysed 40% or more of the target cells. IgG antibodies against nuclear antigens were detected by an indirect immunofluorescence technique using cryostat sections of mouse liver as antigenic substrate, as described (7). IgG autoantibodies against double-stranded DNA (dsDNA) were determined by an indirect immunofluorescence technique using the extranuclear dsDNA of Crithidia luciliae as antigenic substrate, as described (7). For the determination of both antinuclear and anti-dsDNA antibodies, the initial dilution of mouse serum was 1 in 10; the highest serum dilution at which specific immunofluorescence was seen was called the titer.

Results

Lyt Subsets of Donor T Cells Involved in the Induction of LGVHD in Nonirradiated $F_1$ Mice. In order to determine which donor T-cell subset(s) is (are) responsible for the induction of LGVHD, groups of nonirradiated BDF1 mice were injected
FIGURE 1. Induction of LGVHD as a function of the Lyt subsets of parental T cells administered. Groups of nonirradiated BDF1 mice were injected on both day 0 and day 7 with a mixture of $5 \times 10^7$ viable B10 donor cells; the original mixture was composed of one-third lymph node cells and two-thirds spleen cells. The B10 donor cells had been pretreated either once (A) or twice (B), as indicated. Each of the groups of BDF1 mice, which had received the donor cells pretreated once, consisted of 15 mice; the groups of BDF1 mice, which had received the donor cells pretreated twice, consisted of 10 mice each.

with various inocula, each of which contained $10^8$ viable B10 cells. As expected, the vast majority (73%) of the F1 recipients of B10 cells that had been treated once with NMS succumbed to a typical acute GVHD (Fig. 1A); their LGVHD was always preceded by a 20–30% reduction of the hematocrit values (hematocrit values of N F1 mice ranging from 43 to 48). None of the F1 recipients of anti-Thy-1-treated B10 cells developed acute GVHD, not to mention LGVHD (Fig. 1A); consistent with this observation, the hematocrit values of these F1 recipients were normal (ranging from 42 to 48). Treatment of the B10 donor cells with anti-Lyt-2 completely abolished their capacity to induce acute GVHD and LGVHD; none of the GVH F1 mice of this group had reduced hematocrit values. After a single treatment of the B10 donor cells with anti-Lyt-1, one-third of the F1 recipients still developed acute GVHD (hematocrit values between 30 and 35) and eventually died from acute GVHD (Fig. 1A). After the donor cells had been treated twice with anti-Lyt-1, however, the inoculum of $10^8$ viable B10 cells had lost its capacity to induce LGVHD (Fig. 1B) and even acute GVHD (hematocrit values ranging from 43 to 48). Donor cells, which had been treated twice with
Development of SLE-like GVHD in Nonirradiated BDF₁ Mice as a Function of the Lyt Subset of Parental T Cells Administered

| Group | Pretreatment of B₁₀ donor cells \(^{5}\) | Nonirradiated BDF₁ recipients: \(^{*}\) Cumulative percentage of surviving mice (week 16) with autoantibodies against | Percentage of mice with ICGN \(^{4}\) |
|-------|---------------------------------|-------------------------------------------------|-----------------|
|       |                                 | Number of mice tested | Thymocytes | Erythrocytes | Nuclear antigens (titer) \(^{3}\) | dsDNA (titer) \(^{3}\) |
| 1     | NMS                             | 4                   | 0          | 0            | 50 (1/40–1/160) | 0 (–) | 0 |
| 2     | Anti-Thy-1                      | 15                  | 0          | 0            | 20 (1/20–1/160) | 0 (–) | 0 |
| 3     | Anti-Lyt-1                      | 10                  | 10         | 0            | 20 (1/40–1/160) | 0 (–) | 0 |
| 4     | Twice anti-Lyt-1                | 10                  | 0          | 0            | 10 (1/80)        | 0 (–) | 0 |
| 5     | Anti-Lyt-2                      | 15                  | 100        | 93           | 100 (1/160–1/2,560) | 40 (1/20–1/160) | 35 |

\(^{*}\) All mice received a total of 10⁸ viable donor cells; the cells were administered in two equal portions on day 0 and day 7. The original donor-cell inocula were composed of 2 parts of spleen cells and 1 part of lymph node cells.

\(^{5}\) Unless mentioned otherwise, the donor cell inocula were pretreated once. After treatment, all inocula were adjusted to the number of viable cells.

\(^{3}\) Represents the number of mice that did not die from acute GVHD (see Fig. 1). Group 1, 2, 3, and 5 initially consisted of 15 recipient mice; group 4 initially consisted of 10 recipient mice.

NMS, had retained their capacity to induce LGVHD (Fig. 1B). These findings indicate that the donor T cells involved in the induction of acute GVHD must be Lyt-2\(^{+}\) as well as Lyt-1\(^{+}\).

The Donor T Cells That Cause SLE-Like GVHD in Nonirradiated F₁ Recipients Carry the Lyt-1\(^{+}\)2\(^{-}\) Phenotype. The above-described nonirradiated F₁ recipients, which had been studied for acute GVHD and LGVHD, were also studied for the development of SLE-like GVHD (Table I). In addition, we studied control groups, each of which consisted of eight syngeneically injected BDF₁ or B₁₀ recipient mice. The syngeneic cells injected were either NMS-, anti-Lyt-1-, or anti-Lyt-2-treated. None of these control mice produced antibodies to thymocytes, erythrocytes, or dsDNA, let alone developed ICGN. Only one or two animals out of each of these groups produced autoantibodies against nuclear antigens. The maximal titer of these antibodies ranged from 1 in 40, to 1 in 160 (data not shown).

All groups of F₁ mice injected with antiserum-treated B₁₀ donor cells initially consisted of 10 or 15 mice but, as already described in Fig. 1, many of the F₁ recipients in groups 1 and 3 of Table I had died from acute GVHD before the end of the experiment (week 16 after the first administration of B₁₀ cells). However, none of these mice showed detectable amounts of lupus-like autoantibodies in their sera or had developed elevated proteinuria as a sign of ICGN (data not shown).

Group 5 in Table I shows that treatment with anti-Lyt-2 rendered the B₁₀ cells capable of inducing an SLE-like autoimmune disease in the BDF₁ recipients. Already 2 wk after the first injection of donor cells, 55% of the F₁ mice had autoantibodies to thymocytes, nuclear antigens, and erythrocytes. At 4 wk after the induction of the GVHR, 100% of the F₁ recipients had autoantibodies to thymocytes and nuclear antigens in their serum, and 93% were Coombs'-positive. All F₁ recipients in this group remained positive for autoantibodies to thymocytes
and nuclear antigens until week 16. Moreover, 40% of the F1 recipients had autoantibodies to dsDNA in their serum at one or more times tested; and severe ICGN, as indicated by elevated proteinuria and immunofluorescence studies, was observed in 33% of the F1 recipients.

In marked contrast, none of the other GVH F1 mice shown in Table I (groups 1 to 4) had comparable symptoms of SLE-like GVHD. None of them showed elevated proteinuria or immunohistological evidence of ICGN, and none of them had autoantibodies against erythrocytes and dsDNA. The titers of antinuclear antibodies, if present at all, did not exceed the titers found in syngeneically injected control mice. Although the percentage of GVH F1 mice with antinuclear antibodies was increased in the F1 recipients of NMS-treated B10 donor cells (group 1), this percentage (50%) represents only two long-term survivors out of the initial group of 15 GVH F1 mice. As expected, treatment of the B10 donor cells with anti-Lyt-1 did not render them capable of inducing SLE-like GVHD (groups 3 and 4).

Subpopulations of Donor T Cells Involved in the Induction of LGVHD in Irradiated F1 Recipients. Since ≈70% of the peripheral T cells in the mouse express the Lyt-2 antigen (15), the total number of T cells among 10⁶ viable Lyt-2-depleted B10 cells comprised only about one-third of the total number of T cells in NMS-treated cells. This total number of donor T cells after the anti-Lyt-2 treatment might therefore have been too low to induce acute GVHD and thus caused SLE-like GVHD in the nonirradiated F1 recipients used. This explanation is unlikely though because small doses of untreated B10 donor cells (5 × 10⁶ to 30 × 10⁶, 2 parts spleen cells and 1 part lymph node cells) induced only a limited antibody formation and failed to induce SLE-like GVHD (data not shown). To further exclude this possibility comparable numbers of viable antiserum-treated B10 T cells were injected into irradiated BDF1 recipients. In order to adjust the various donor cell inocula to comparable numbers of viable T cells, B10 spleen cells that had been treated twice with either NMS, anti-Lyt-1, or anti-Lyt-2, were passed through nylon-wool columns.

First, we determined the alloreactivity of these three suspensions of B10 T cells by means of the primary anti-SRBC response in vitro (Fig. 2). Low numbers of NMS-treated B10 T cells induced allohelp; higher numbers induced allo-suppression. The anti-Lyt-2-treated B10 T cells exclusively induced allohelp, and the anti-Lyt-1-treated B10 T cells were ineffective. These results are consistent with those reported elsewhere (12, 13).

Fig. 3 shows the different capacities of the same three suspensions of B10 T cells to induce LGVHD in irradiated BDF1 mice were used, because they irradiated F1 recipients are much more susceptible than nonirradiated ones to the induction of LGVHD (11, 16). Whereas 90% of the F1 recipients of the NMS-treated B10 T cells developed LGVHD, only one (10%) of the recipients of anti-Lyt-2-treated T cells died, and none of the F1 recipients of anti-Lyt-1-treated B10 T cells died.

Subset of Donor T Cells Causing Chronic GVHD in Irradiated F1 Mice. The same groups of irradiated BDF1 mice that had been used for studying LGVHD were also used for testing the presence of SLE-like autoantibodies in the serum (Table II). None of the F1 recipients that died from acute GVHD before the end of the
Lyt SUBSETS OF DONOR T CELLS IN GVH REACTIONS

FIGURE 2. Allogeneic effects caused by Lyt subsets of B10 T cells in vitro. The effects of B10 T cells on the primary PFC responses of SRBC-stimulated BDF1 B cells were compared. Each culture contained $3 \times 10^6$ T-cell-depleted BDF1 spleen cells (B cells). As a source of T cells, graded numbers of live B10 spleen cells that had been treated twice, as indicated, were used; after the second treatment, these cells were passed through nylon-wool columns, adjusted to the same number of live cells, and added to the B cell cultures. The three T-cell suspensions tested here are the same that were used to perform the GVH experiments described in Fig. 3 and Table II.

FIGURE 3. Induction of LGVHD in irradiated BDF1 recipients as a function of the Lyt subsets of parental T cells administered. Groups of 750-rad irradiated BDF1 mice were first repopulated with $3 \times 10^7$ syngeneic (BDF1) spleen cells and on the following day injected with $10^7$ viable B10 cells as a source of T cells. The T cells were obtained from B10 spleen cells that had been pretreated twice, as indicated; thereafter, the cells had been passed over nylon-wool. The resulting cell suspensions were adjusted to the same concentration of live cells and then injected into the recipients. Each group of recipients initially consisted of 10 F1 mice.

Observation period (week 16) had shown autoantibodies before they died. In Table II, therefore, only the results obtained from the surviving GVH F1 mice are shown. It is evident from the Table that the vast majority of the F1 recipients of anti-Lyt-2-treated donor cells showed a vigorous formation of SLE-like auto-
Table II

Formation of SLE-like Autoantibodies in Irradiated BDF1 Mice as a Function of the Lyt Subsets of B10 T Cells Administered

| T cells obtained from B10 donors* | Irradiated BDF1 recipients: Cumulative percentage of surviving F1 mice with autoantibodies against |
|----------------------------------|-------------------------------------------------------------|
| Number of live cells administered (x 10^6) | Pretreatment of cells | Number tested | Thymocytes | Erythrocytes | Nuclear antigens (titer) | dsDNA (titer) |
|----------------------------------|-----------------|--------------|-----------|------------|----------------|----------------|
| 0                                | NMS             | 10           | 0         | 0          | 20 (1/20-1/160) | 0 (-)               |
| 10                               | Anti-Lyt-1      | 10           | 0         | 0          | 100 (1/160)     | 0 (-)               |
| 10                               | Anti-Lyt-2      | 9            | 100       | 78         | 100 (1/40-1/2,500) | 78 (1/40-1/80) |

* Same cells as those used for the experiments described in Figs. 2 and 3.
† Same mice as those used for the experiment shown in Fig. 3.
‡ Represents the numbers of F1 recipients that had survived until the end of the experiment, i.e. week 16, after the injection of B10 cells. At the start of the experiment, each group consisted of 10 F1 mice.
§ Range of maximal serum titers of positive F1 mice.

antibodies. In contrast, neither NMS-treated nor anti-Lyt-1-treated B10 T cells were capable of inducing a comparable autoantibody formation in the recipients.

Discussion

The results of the present study indicate that, depending on the Lyt phenotype of the parental T lymphocytes injected, the F1 recipients developed either acute or chronic GVHD.

Stimulatory or Chronic GVHD. In previous studies, it was shown that injection into nonirradiated BDF1 recipients of unseparated B10 T cells led to only limited autoantibody formation (2) and failed to induce ICGN but, instead, caused acute GVHD and LGVHD (10). Using the same parent → F1 combination, now we showed that depletion of the allosuppressive Lyt-2+ cells rendered the B10 donor cells capable of inducing a severe SLE-like autoimmune disease that included the development of ICGN (Table I). The mechanism underlying the formation of autoantibodies during the GHVR is thought to be a positive allogeneic effect caused by abnormal T-B-cell cooperation (3, 7, 8, 17-21). In this process, T cell help is provided by parental T cells that react against the allogeneic class-II (I-A/I-E) antigens of the F1 recipient's H-2 complex (3, 8). The excess of T cell help generated by this reaction, in combination with certain self-antigens, triggers those F1 B cells capable of producing autoantibodies characteristic of SLE (3, 7, 8, 17, 21). The autoantibodies in turn form immune complexes and cause ICGN (9). In the present study, we showed that the production of multiple autoantibodies and ICGN during a GVHR requires the injection of Lyt-1+2+ donor cells; that Lyt phenotype is commonly associated with T\(^H\) cells (15, 22, 23), including the T\(^H\) cells that react against allogeneic class-II antigens (Fig. 2; 12, 13). In contrast, the B10 cells that had been pretreated with anti-Lyt-1 were unable to induce vigorous autoantibody formation in the recipients (Table I and II). The latter finding is hardly surprising, however, because virtually all T cells express
Lyt SUBSETS OF DONOR T CELLS IN GVH REACTIONS

at least small amounts of Lyt-1 (24). The low level of antinuclear antibodies observed after the injection of anti-Lyt-1-treated cells barely exceeded that found in syngeneically injected or noninjected BDF₁ mice. This low level of spontaneous autoantibody formation conforms with previous reports (25, 26) that normal mice, especially at higher ages, may have antinuclear antibodies in the serum.

The different forms of GVHD induced by different Lyt subsets of donor T cells argue against the pathogenesis of chronic GVHD postulated by Elkins (1, 27). He proposed that the symptoms of chronic GVHD are only late indirect consequences of the cytotoxic damage and the subsequent infections caused by the initial alloagression by donor T cells. The data presented in the present paper, however, as well as other data (2–4, 7, 8) indicate that stimulatory GVH symptoms can appear already at 2 wk after the initiation of the GVHR and do not require a preceding phase of lymphohemopoietic depletion (acute GVHD); instead, these symptoms are direct consequences of the allo-stimulation induced by donor TH cells. In fact, we observed that removing the Lyt-2⁺ donor T cells, the very cells that are needed for the induction of acute GVHD, was a prerequisite for the induction of SLE-like GVHD by B10 T cells. Nevertheless, viral infections, including those acquired during GVHD, might lead to a GVH-like pathogenesis so that their symptoms are (almost) indistinguishable from those caused by alloreactive donor T cells (6, 17, 21).

Acute GVHD. Following an initial phase of stimulatory symptoms in the first week of the GVHR (1, 2), acute GVHD rapidly produces suppressive pathological symptoms, such as pancytopenia accompanied by aplastic anemia and hypogammaglobulinemia (1–5, 10). This biphasic course has led us to the concept (2) that acute GVHD in H-2-different recipients is due to a sequential activation, first of class-II-reactive donor T or T inducer cells and, thereafter, of class-I-reactive donor T S cells. The activated donor TH cells might cause the initial phase of stimulatory symptoms, and, analogous to other systems (14), induce class-II-reactive donor T S cells. Optimally activated donor T S cells appear to cause the suppressive pathological symptoms of GVHD (2–4, 10, 28, 29).

In the present paper, we showed the alloreactive B10 cells carrying the Lyt-1⁺2⁻ phenotype were unable, or almost unable, to induce acute GVHD and LGVHD in either nonirradiated or irradiated H-2-different F₁ mice (Figs. 1 and 3). This finding is consistent with the results published by Korngold and Sprent (30), who showed that Lyt-1⁺2⁻ donor T cells were unable to induce LGVHD in irradiated recipients differing from the donor at multiple non-H-2 loci. Our findings differ, however, from the studies reported by Valera et al. (16). Valera et al. studied the Lyt phenotype of the donor T cells responsible for the induction of LGVHD in irradiated recipients, which differed from the donor at all of H-2 as well as non-H-2 loci. They found that treatment of the donor cells with anti-Lyt-2 did not protect the recipient mouse from LGVHD. The most likely explanation for this discrepancy with our data is that the single anti-Lyt-2 treatment of the donor cells used by Valera et al. (16) was not sufficient to remove all of the Lyt-2⁺ T cells and that the few spared T cells were responsible for the observed LGVHD in the irradiated recipients. In our hands, a single treatment with anti-Lyt-2 or alloreactive T cells often proved to be ineffective in abolishing their allosuppressor capacity in vitro (data not shown). In fact, Valera et al. (16)
ROLINK AND GLEICHMANN

555

reported that their treatment with anti-Lyt-2 did not completely abrogate the
capacity of the donor cells to generate anti-host T killer cells in vitro. Others
(15, 31), by contrast, have shown that T cells properly depleted of Lyt-2+ cells
were no longer capable of generating cytotoxic T cells across an H-2 difference.
The possibility that, indeed, a very low number of spared Lyt-2+ T cells might
have caused the LGVHD observed by Valera et al. (16) receives further support
by previous findings made by Korngold and Sprent (11). These authors observed
that parental bone marrow cells, which contained as few as 0.3% mature T cells,
i.e. 3 × 10⁴ T cells, sufficed to induce LGVHD in irradiated F₁ recipients that
differed at multiple non-H-2 loci only. Moreover, very similar observations have
recently been made in human recipients of HLA-different bone marrow grafts
(32).

In agreement with Korngold and Sprent (30) and Valera et al. (16) we found
that Lyt-1-2+ T cells, too, are unable to induce LGVHD. Together with the
observed inability of Lyt-1+2- cells to induce LGVHD, the combined results lead
to the conclusion that donor T cells carrying the Lyt-1+2+ phenotype must be
involved in the pathogenesis of LGVHD. This conclusion is identical with that
of Korngold and Sprent (30). It is not yet known, however, whether Lyt-1+2-
inducer T cells are required in addition to the Lyt-1+2+ donor cells.

As already mentioned, we think that alloreactive donor T⁵ cells are the effector
cells that cause the pancytopenia of acute GVHD (3, 4, 10). Our conclusion that
donor Lyt-1+2+ cells must be involved in the pathogenesis of LGVHD is consist-
ent with this concept, because several groups of investigators showed that the
severe allosuppression at the beginning of the second phase of acute GVHD, i.e.
at about day 7, is caused by Lyt-1+2+ donor T cells (33–35). Furthermore,
recently we provided evidence that allosuppression induced in vitro also requires
Lyt-1+2+ cells, because neither Lyt-1-2+ cells alone nor a mixture consisting of
Lyt-1+2- cells and increasing numbers of Lyt-1-2+ cells were able to induce
allosuppression across a full H-2 difference (13). These studies also showed that
a class-II-reactive Lyt-1+2+ cell causes allohelp, whereas allosuppression in vitro
appears to be caused by a class-I-reactive Lyt-1+2+ cells. Thus, the data of the
present study have closed the gap between the studies performed in vitro (13)
and the GVH experiments performed in vivo. In combination with previous
findings (3, 8), we conclude that stimulatory GVHD is caused by class-II-reactive
Lyt-1+2+ donor T⁴ cells. In contrast, the development of suppressive GVHD
seems to require class-I-reactive Lyt-1+2+ T⁵ cells and, possibly also class II-
reactive Lyt-1+2- inducer cells of the donor. However, experiments involving
positively selected Lyt-1+2+ cells will have to be performed in order to verify this
concept.

Summary

Previous work from this laboratory has led to the hypothesis that the stimula-
tory pathological symptoms of chronic graft-vs.-host disease (GVHD) are caused
by alloreactive donor T helper (T⁴) cells, whereas the suppressive pathological
symptoms of acute GVHD are caused by alloreactive T suppressor (T⁵) cells of
the donor. In the present paper we analyzed the Lyt phenotypes of B10 donor
T cells required for the induction of either acute or chronic GVHD in H-2-
different (B10 × DBA/2)F1 recipients. First, nonirradiated F1 mice were used as the recipients. We found that unseparated B10 T cells induced only a moderate formation of systemic lupus erythematosus (SLE)-like autoantibodies, but a high percentage of lethal GVHD (LGVHD). In contrast, Lyt-1\(^+\)2\(^-\) donor T cells were unable to induce LGVHD in these recipients; these cells were capable, however, of inducing a vigorous formation of SLE-like autoantibodies and the formation of severe immune-complex glomerulonephritis. Lyt-1\(^-\)2\(^+\) T cells were incapable of inducing either acute or chronic GVHD.

In another experiment, the sensitivity and accuracy of the GVH system were increased by using irradiated F1 mice as recipients and by comparing donor-cell inocula that contained similar numbers of T lymphocytes. In addition, donor-cell inocula were used that had been tested for their allohelper and allosuppressor effects on F1 B cells in vitro. In the irradiated F1 recipients, too, unseparated donor T cells were superior to T cell subsets in inducing LGVHD; Lyt-1\(^-\)2\(^+\) donor cells were completely and Lyt-1\(^+\)2\(^-\) donor cells were almost incapable of doing so. In contrast, Lyt-1\(^+\)2\(^-\) T cells, but neither unseparated T cells nor Lyt-1\(^-\)2\(^+\) T cells, were capable of inducing a vigorous formation of SLE-like autoantibodies. We conclude that the stimulatory pathological symptoms of chronic GVHD are caused by Lyt-1\(^+\)2\(^-\) allohelper T cells. In contrast, the development of the suppressive pathological symptoms of acute GVHD appears to involve alloreactive Lyt-1\(^-\)2\(^+\) T suppressor cells.

We thank Walter van der Meer for giving excellent technical assistance. Drs. L. Aarden, C. J. M. Melief, and M. Schreier are thanked for critical reading of the manuscript.

Received for publication 8 February 1983 and in revised form 2 May 1983.

References
1. Elkins, W. L. 1971. Cellular immunology and the pathogenesis of graft versus-host reactions. *Prog. Allergy*. 15:78.
2. Pals, S. T., T. Radaszkiwicz, and E. Gleichmann. 1982. Induction of either acute or chronic graft-versus-host disease due to genetic differences among donor T cells. In *In vivo Immunology: Histopathology of the Lymphoid System*. P. Nieuwenhuis, A. A. van den Broek, and M. G. Hanna Jr., editors. Plenum Press, New York. p. 537.
3. Rolink, A. G., S. T. Pals, and E. Gleichmann. 1983. Allosuppressor- and allohelper T cells in acute and chronic graft-versus-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A. *J. Exp. Med.* 157:755.
4. Rolink, A. G., T. Radaszkiwicz, S. T. Pals, W. G. J. van der Meer, and E. Gleichmann. 1982. Allosuppressor and allohelper T cells in acute and chronic graft-versus-host disease. I. Alloreactive suppressor cells rather than killing T cells appear to be the decisive effector cells in lethal graft-versus-host disease. *J. Exp. Med.* 155:1501.
5. Armstrong, M. Y. K., R. S. Schwartz, and L. Beldotti. 1967. Neoplastic sequence of allogeneic disease. III. Histological events following transplantation of allogeneic spleen cells. *Transplantation*. 5:1380.
6. Gleichmann, E., H. Gleichmann, and W. Wilke. 1976. Autoimmunization and lymphomagenesis in parent → F1 combinations differing at the major histocompatibility complex: model for spontaneous disease caused by altered self-antigens? *Transplant. Rev.* 31:156.
7. Gleichmann, E., E. H. van Elven, and J. P. W. van der Veen. 1982. A systemic lupus...
erythematosus-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. *Eur. J. Immunol.* 12:152.

8. Rappard-van der Veen, F. M. van, A. G. Rolink, and E. Gleichmann. 1982. Diseases caused by reactions of T lymphocytes towards incompatible structures of the major histocompatibility complex. VI. Autoantibodies characteristic of systemic lupus erythematosus induced by abnormal T-B-cell cooperation across I-E. *J. Exp. Med.* 155:1555.

9. Rolink, A. G., H. Gleichmann, and E. Gleichmann. 1983. Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex. VII. Immune-complex glomerulonephritis. *J. Immunol.* 130:209.

10. Elven, E. H. van, A. G. Rolink, F. van der Veen, and E. Gleichmann. 1981. The capacity of genetically different T lymphocytes to induce lethal graft-versus-host disease correlates with their capacity to generate suppression but not their capacity to generate anti-F1 killer cells. A non-H-2 locus determines the inability to induce lethal graft-versus-host disease. *J. Exp. Med.* 153:1474.

11. Korngold, R., and J. Sprent. 1978. Lethal graft-versus-host disease after bone-marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. *J. Exp. Med.* 148:1687.

12. Cantor, H., and E. A. Boyse. 1976. Regulation of cellular and humoral immune responses by T-cell subclasses. *Cold Spring Harbor Symp. Quant. Biol.* 41:23.

13. Rolink, A. G., W. G. J. van der Meer, C. J. M. Melief, and E. Gleichmann. 1983. Intra-H-2 and T-cell requirements for the induction of maximal positive and negative allogeneic effects in vitro. *Eur. J. Immunol.* 13:191.

14. Cantor, H., and D. K. Gershon. 1978. Immunological circuits: cellular composition. *Fed. Proc.* 38:2058.

15. Cantor, H., and E. A. Boyse. 1975. Functional subclasses of T cells bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen. *J. Exp. Med.* 141:1376.

16. Valera, D. A., C. C. B. Soderling, and J. H. Kersey. 1982. Bone-marrow transplantation across major histocompatibility barrier in mice. II. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. *J. Immunol.* 128:871.

17. Gleichmann, E., and H. Gleichmann. 1980. Spectrum of diseases caused by alloreactive T cells, mode of sensitization to the drug diphenylhydantoin, and possible role of SLE-typical self-antigens in B-cell triggering. In Immunoregulation and Autoimmunity. R. S. Krakauer and M. K. Cathcart, editors. Elsevier/North-Holland, New York. p. 73.

18. Bretscher, P. 1973. Hypothesis: a model for generalized autoimmunity. *Cell Immunol.* 6:1.

19. Allison, A. C., A. M. Denman, and R. D. Barnes. 1971. Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity. *Lancet.* 2:135.

20. Katz, D. H. 1977. Lymphocyte differentiation, recognition, and regulation. Academic Press Inc., New York, p. 482.

21. Gleichmann, E., A. G. Rolink, S. T. Pals, and H. Gleichmann. 1983. Graft-versus-host reactions: clues to the pathogenesis of a broad spectrum of immunological disease. *Transplant. Proc.* 15:1436.

22. Shiku, H., P. Kisielow, M. A. Bean, T. Takahashi, E. A. Boyse, H. F. Oettgen, and L. J. Old. 1975. Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. *J. Exp. Med.* 141:227.

23. Kisielow, P., J. A. Hirst, H. Shiku, P. C. L. Beverly, M. K. Hoffmann, E. A. Boyse, and H. F. Oettgen. 1975. Ly antigens as markers for functionally distinct subpopu-
lutions of thymus-derived lymphocytes of the mouse. *Nature (Lond.)*. 253:219.

24. Ledbetter, J. A., R. V. Rouse, H. S. Micklem, and L. A. Herzenberg. 1980. T-cell subsets defined by expression of Lyt 1,2,3 and Thy-1 antigens. Two parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. *J. Exp. Med.* 152:280.

25. Veen, J. L. ten, and T. E. W. Feltkamp. 1972. Studies on drug-induced lupus erythematosus in mice. I. Drug-induced antinuclear antibodies. *Clin. Exp. Immunol.* 11:265.

26. Shulman, L. E., J. M. Grumpel, W. A. D'Angelo, R. L. Sokhami, M. B. Stevens, A. S. Townes, and A. T. Masi. 1964. Antinuclear factor in inbred strains of mice: the possible role of environmental influence. *Arthritis Rheum.* 7:758.

27. Elkins, W. L. 1979. Tolerance and the fate of the allogeneic bone-marrow chimaera. *In Immunological Tolerance and Enhancement*. F. P. Stuart, and F. W. Fitch, editors. MTP Press Ltd., Lancaster, U. K. p. 1.

28. Tigelaar, R. E., and R. Asofsky. 1972. Synergy among lymphoid cells mediating the graft-versus-host response. IV. Synergy in the GVH reaction quantitated by a mortality assay in sublethally irradiated recipients. *J. Exp. Med.* 135:1059.

29. Pickel, K., and M. K. Hoffmann. 1977. Suppressor T cells arising in mice undergoing a graft-versus-host response. *J. Immunol.* 118:653.

30. Korngold, R., and J. Sprent. 1982. Features of T cells causing H-2-restricted lethal graft-versus-host disease across minor histocompatibility barriers. *J. Exp. Med.* 155:872.

31. Simon, M. M., and K. Eichmann. 1980. T cell subsets participating in the generation of cytotoxic T cells. *Springer Semin. Immunopathol.* 3:39.

32. Reinherz, E. L., R. Geha, J. M. Rappeport, M. Wilson, A. C. Penta, R. E. Hussey, K. A. Fitzgerald, J. F. Daley, H. Levine, F. S. Rosen, and S. Schlossman. 1982. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone-marrow for severe combined immunodeficiency. *Proc. Natl. Acad. Sci. USA.* 79:6047.

33. Hurtenbach, U., and G. M. Shearer. 1983. Analysis of murine T lymphocyte markers during the early phases of GVH-associated suppression of cytotoxic T-lymphocyte responses. *J. Immunol.* 130:1561.

34. Shand, F. L. 1977. Ly and Ia phenotype of suppressor T cells induced by graft-versus-host reaction. *Eur. J. Immunol.* 7:746.

35. Pickel, K., and M. K. Hoffmann. 1977. The Ly phenotype of suppressor T cells arising in mice subjected to a graft-versus-host reaction. *J. Exp. Med.* 145:1169.